PLAS-FREE

Company Overview

Snapshot

Founded in August 2017 by Zeev Dvashi and Abed Elrauf Hijazi, PLAS-FREE operates with 11–50 employees. The company has secured $9.22 million across six funding rounds. In August 2017, PLAS-FREE received seed funding from NGT3.

Business overview

PLAS-FREE is an Israel-based company specializing in the development of blood filtration systems within the Health Tech & Life Sciences sector. Its core product, ClearPlasma, is a single-use device designed to extract plasminogen from plasma units to enhance coagulation and promote hemostasis. The company is also developing the Ammonia Adsorption Column-300 (AAPC-300) to reduce toxic accumulation in patients with liver failure. PLAS-FREE serves the healthcare market, particularly hospitals and healthcare providers, by integrating bio-convergence to advance innovative medical device solutions.

Strategic signal

In February 2024, PLAS-FREE was featured in TheMarker, highlighting its life-saving technology. This media attention signals growing recognition and validation of the company's innovative medical devices within the Israeli medical ecosystem, potentially attracting further investment and strategic partnerships as it advances its clinical trials and product development.

Company Intelligence Q&A

What is PLAS-FREE's primary product?

PLAS-FREE's primary product is ClearPlasma, a single-use device designed to extract plasminogen from plasma units for transfusion. This process enhances coagulation and promotes hemostasis.

When was PLAS-FREE founded and by whom?

PLAS-FREE was founded in August 2017 by Zeev Dvashi and Abed Elrauf Hijazi.

Has PLAS-FREE received any non-equity funding?

In October 2019, PLAS-FREE received a grant from EU Horizon 2020. Additionally, in December 2021, the company received a grant from the MedTech Startup Contest.

What is the Ammonia Adsorption Column-300 (AAPC-300)?

The Ammonia Adsorption Column-300 (AAPC-300) is a technology under development by PLAS-FREE, designed to reduce toxic accumulation in patients with liver failure. This technology is currently in pre-clinical trials.

What recognition did PLAS-FREE receive in July 2021?

In July 2021, PLAS-FREE won 2nd place at BIO Digital 2021, an event that recognizes innovation in the biotech industry.